Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: A randomized, controlled phase III trial

Journal of Clinical Oncology

Volumn 30, Issue 29, 2012, Pages 3640-3647

  Ramlau, Rodryg ^a   Gorbunova, Vera ^b   Ciuleanu, Tudor Eliade ^c   Novello, Silvia ^d   Ozguroglu, Mustafa ^e   Goksel, Tuncay ^f   Baldotto, Clarissa ^g   Bennouna, Jaafar ^h   Shepherd, Frances A ^j   Le Guennec, Solenn ⁱ   Rey, Augustin ⁱ   Miller, Vincent ^k   Thatcher, Nicholas ^l   Scagliotti, Giorgio ^d  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^d UNIVERSITY OF TURIN   (Italy)

^e ISTANBUL UNIVERSITY   (Turkey)

^f EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^g INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^h CENTRE RENÉ GAUDUCHEAU   (France)

ⁱ SANOFI   (France)

^j UNIVERSITY OF TORONTO   (Canada)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l CHRISTIE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; ERLOTINIB; GEMCITABINE; NAVELBINE; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VASCULOTROPIN; VINCA ALKALOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BLEEDING; BONE METABOLISM; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSGEUSIA; DYSPHAGIA; DYSPHONIA; DYSPNEA; EPISTAXIS; EXPLORATORY RESEARCH; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HEADACHE; HUMAN; HYPERTENSION; IMMUNOGENICITY; LACRIMATION DISORDER; LIVER METASTASIS; LOG RANK TEST; LUNG EMBOLISM; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PLEURA METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMATITIS; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PLATINUM; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84867602821     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.6932     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
2. Yang P, Allen MS, Aubry MC, et al: Clinical features of 5,628 primary lung cancer patients: Experience at Mayo Clinic from 1997 to 2003. Chest 128:452-462, 2005 (Pubitemid 40994510)
3. Spiro SG, Rudd RM, Souhami RL, et al: Chemotherapy versus supportive care in advanced non-small cell lung cancer: Improved survival without detriment to quality of life. Thorax 59:828-836, 2004 (Pubitemid 39389621)
4. Georgoulias V, Ardavanis A, Agelidou A, et al: Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial. J Clin Oncol 22:2602-2609, 2004 (Pubitemid 41103747)
5. Gicquel C, Baudin E, Lebouc Y, et al: Adrenocortical carcinoma. Ann Oncol 8:423-427, 1997 (Pubitemid 27310684)
6. Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373:1525-1531, 2009
7. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
8. Azzoli CG, Temin S, Aliff T, et al: 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Updateon Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 29:3825-3831, 2011
9. Riely GJ, Miller VA: Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res 13:s4623-s4627, 2007
10. Leighl NB, Raez LE, Besse B, et al: A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 5:1054-1059, 2010
11. Isambert N, Freyer G, Zanetta S, et al: A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: Preliminary results. J Clin Oncol 26:177s, 2008 (suppl; abstr 3599)
12. Novello S, Ramlau R, Gorbunova V, et al: Aflibercept in combination with docetaxel for second-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC): Final results of a multinational placebo-controlled phase III trial (EFC10261-VITAL). J Thorac Oncol 6:2S, 2011 (abstr 511)
13. Herbst RS, Sun Y, Eberhardt WE, et al: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. Lancet Oncol 11:619-626, 2010
14. Fossella F, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362, 2000 (Pubitemid 30415821)
15. Herbst RS, Ansari R, Bustin F, et al: Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial. Lancet 377:1846-1854, 2011
16. Shepherd F, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000 (Pubitemid 30324363)
17. Pectasides D, Pectasides M, Farmakis D, et al: Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: A randomized phase II trial. Ann Oncol 16:294-299, 2005 (Pubitemid 40309313)
18. Schuette W, Nagel S, Blankenburg T, et al: Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23:8389-8395, 2005
19. Hanna N, Shepherd FA, Fossella F, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004 (Pubitemid 41079796)
20. Brundage MD, Davies D, Mackillop WJ: Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 122:1037-1057, 2002
21. Scagliotti G, Hanna N, Fossella F, et al: The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. Oncologist 14:253-263, 2009
22. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
23. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008
24. de Boer RH, Arrieta O, Yang CH, et al: Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: A randomized, double-blind phase III trial. J Clin Oncol 29:1067-1074, 2011
25. Scagliotti G, Krzakowski M, Szczesna A, et al: Sunitinib (SU) in combination with erlotinib (E) for the treatment of advanced/metastatic nonsmall cell lung cancer (NSCLC): A phase III study. Ann Oncol 21:viii3, 2010 (abstr LBA6)
26. Ranpura V, Hapani S, Wu S: Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis. JAMA 305:487-494, 2011